Patient-reported outcomes (PRO) from a global phase 3 randomized controlled trial (RCT) of inotuzumab ozogamicin (InO) vs standard care (SC) for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL).
2016 ◽
Vol 34
(15_suppl)
◽
pp. 7027-7027
2018 ◽
2018 ◽
2019 ◽
Vol 23
(12)
◽
pp. 4355-4363
◽
2012 ◽
Vol 97
(Suppl 2)
◽
pp. A122-A122